SRX Global acquires CERo senior secured debt
Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The investment provides CERo with additional capital to advance its clinical programs, potentially boosting its valuation and development prospects. For SRX Global, the secured debt investment aligns with its strategy of investing in high-conviction companies, potentially enhancing its portfolio returns.
SRX Global Inc., an AI-enabled investment platform, announced on August 31, 2026, that it has purchased senior secured debt in Coeptis Therapeutics Holdings, Inc., a cellular immunotherapy company developing engineered T cell therapeutics. The investment is intended to provide CERo with additional capital to accelerate its clinical programs, particularly the advancement of its lead candidate CER-1236 in the Phase 1 CERTAIN-T trial for hematologic malignancies. SRX Global's CEO, Alex Cunningham, highlighted the strategic fit and the clinical progress of CER-1236. CERo has treated six patients in the ongoing trial, with no dose-limiting toxicities observed in the most recent cohort, and has initiated the third planned cohort, which will include patients with myelodysplastic syndromes and myelofibrosis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard